Shai S. Erlich
Director Técnico/Científico/I+D en Quark Pharmaceuticals, Inc. .
Cargos activos de Shai S. Erlich
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Director Técnico/Científico/I+D | 27/09/2010 | - |
| Corporate Officer/Principal | 01/01/1999 | 27/09/2010 |
Historial de carrera de Shai S. Erlich
Formación de Shai S. Erlich.
| Ben-Gurion University of the Negev | Undergraduate Degree |
| Tel-Aviv University | Graduate Degree |
| Icahn School of Medicine at Mount Sinai | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 3 |
| Israel | 3 |
Operativa
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Consumer Services | 4 |
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Shai S. Erlich
- Experiencia
